| Jul 22 |
99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society
|
| Jul 22 |
IceCure Medical receives Nasdaq compliance notice
|
| Jul 19 |
IceCure Medical receives non-compliance notice for continued listing from Nasdaq
|
| Jul 19 |
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
|
| Jul 11 |
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
|
| Jul 9 |
European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer
|
| Jul 3 |
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
|
| Jul 2 |
FDA grants marketing authorisation for IceCure’s XSense Cryoablation System
|
| Jul 1 |
U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes
|
| Jun 24 |
We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate
|
